Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HUMAOTCMKTS:IPHYFNASDAQ:ITOSNASDAQ:TECX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHUMAHumacyte$2.37-1.7%$1.91$1.15▼$9.79$367.63M23.87 million shs2.72 million shsIPHYFInnate Pharma$1.74$1.49$1.45▼$1.76$145.45M0.41,445 shsN/AITOSiTeos Therapeutics$10.17+1.9%$7.84$4.80▼$18.13$389.25M1.51673,504 shs1.11 million shsTECXTectonic Therapeutic$21.89-2.5%$20.58$13.70▼$61.07$408.75M3.25173,408 shs155,942 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHUMAHumacyte0.00%-8.49%+25.40%-22.04%-67.71%IPHYFInnate Pharma0.00%+19.66%+19.66%-40.17%-35.02%ITOSiTeos Therapeutics0.00%0.00%+27.60%+38.93%-38.25%TECXTectonic Therapeutic0.00%-5.07%+5.80%-14.59%+2,188,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHUMAHumacyte2.319 of 5 stars3.51.00.00.02.62.50.6IPHYFInnate Pharma1.2763 of 5 stars0.05.00.00.03.01.70.0ITOSiTeos Therapeutics3.7346 of 5 stars4.14.00.00.02.43.30.6TECXTectonic Therapeutic3.287 of 5 stars3.62.00.00.02.15.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHUMAHumacyte 3.00Buy$11.71394.27% UpsideIPHYFInnate Pharma 0.00N/AN/AN/AITOSiTeos Therapeutics 2.14Hold$15.8655.92% UpsideTECXTectonic Therapeutic 3.25Buy$82.33276.12% UpsideCurrent Analyst Ratings BreakdownLatest IPHYF, TECX, ITOS, and HUMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025TECXTectonic TherapeuticRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$76.006/9/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.006/6/2025TECXTectonic TherapeuticLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$87.006/5/2025TECXTectonic TherapeuticLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/28/2025ITOSiTeos TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$13.00 ➝ $12.005/28/2025ITOSiTeos TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$10.00 ➝ $12.005/15/2025TECXTectonic TherapeuticMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$51.00 ➝ $85.005/14/2025ITOSiTeos TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$16.00 ➝ $13.005/14/2025ITOSiTeos TherapeuticsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$12.005/14/2025ITOSiTeos TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$16.00 ➝ $12.005/14/2025HUMAHumacyteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$4.00(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHUMAHumacyte$517K711.09N/AN/A$0.13 per share18.23IPHYFInnate Pharma$66.71M2.18N/AN/A$0.70 per share2.48ITOSiTeos Therapeutics$35M11.12N/AN/A$16.08 per share0.63TECXTectonic TherapeuticN/AN/AN/AN/A$2.13 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHUMAHumacyte-$110.78M-$0.69N/AN/AN/AN/A-942.81%-93.82%8/12/2025 (Estimated)IPHYFInnate Pharma-$8.19MN/A0.00∞N/AN/AN/AN/AN/AITOSiTeos Therapeutics-$112.64M-$3.04N/AN/AN/AN/A-20.11%-17.50%8/6/2025 (Estimated)TECXTectonic Therapeutic$12.16M-$7.31N/AN/AN/AN/A-35.53%-31.97%8/13/2025 (Estimated)Latest IPHYF, TECX, ITOS, and HUMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025HUMAHumacyte-$0.19-$0.10+$0.09$0.28$0.46 million$0.52 million5/8/2025Q1 2025TECXTectonic Therapeutic-$1.10-$0.93+$0.17-$0.93N/AN/A4/28/2025Q1 2025ITOSiTeos Therapeutics-$0.94-$0.80+$0.14-$0.80$9.35 millionN/A3/28/2025Q4 2024HUMAHumacyte-$0.23-$0.16+$0.07-$0.16$0.64 million$7.23 million3/20/2025Q4 2024TECXTectonic Therapeutic-$1.39-$0.84+$0.55-$0.84N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHUMAHumacyteN/AN/AN/AN/AN/AIPHYFInnate PharmaN/AN/AN/AN/AN/AITOSiTeos TherapeuticsN/AN/AN/AN/AN/ATECXTectonic TherapeuticN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHUMAHumacyteN/A1.101.10IPHYFInnate PharmaN/AN/AN/AITOSiTeos TherapeuticsN/A14.8014.80TECXTectonic TherapeuticN/A9.399.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHUMAHumacyte44.71%IPHYFInnate PharmaN/AITOSiTeos Therapeutics97.16%TECXTectonic Therapeutic62.63%Insider OwnershipCompanyInsider OwnershipHUMAHumacyte5.10%IPHYFInnate Pharma31.89%ITOSiTeos Therapeutics12.50%TECXTectonic Therapeutic38.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHUMAHumacyte150155.12 million111.76 millionOptionableIPHYFInnate Pharma17983.83 million57.10 millionNot OptionableITOSiTeos Therapeutics9038.27 million31.97 millionOptionableTECXTectonic Therapeutic12018.67 million13.40 millionN/AIPHYF, TECX, ITOS, and HUMA HeadlinesRecent News About These CompaniesBrokerages Set Tectonic Therapeutic (NASDAQ:TECX) Target Price at $80.50June 13 at 2:11 AM | americanbankingnews.comRaymond James Begins Coverage on Tectonic Therapeutic (NASDAQ:TECX)June 12 at 3:57 AM | americanbankingnews.comTectonic Therapeutic (NASDAQ:TECX) Coverage Initiated by Analysts at Raymond JamesJune 11, 2025 | marketbeat.comTectonic Therapeutics (TECX) Gains Outperform Rating from Raymond James | TECX Stock NewsJune 10, 2025 | gurufocus.comTectonic Therapeutic (NASDAQ:TECX) Given Average Recommendation of "Buy" by AnalystsJune 8, 2025 | marketbeat.comLifesci Capital Upgrades Tectonic Therapeutic (NASDAQ:TECX) to "Strong-Buy"June 8, 2025 | americanbankingnews.comLifeSci Capital Initiates Coverage of Tectonic Therapeutic (TECX) with Outperform RecommendationJune 7, 2025 | msn.comTectonic Therapeutic (NASDAQ:TECX) Upgraded at Lifesci CapitalJune 7, 2025 | marketbeat.comTectonic Therapeutic (NASDAQ:TECX) Coverage Initiated by Analysts at Lifesci CapitalJune 7, 2025 | americanbankingnews.comTectonic Therapeutic Holds 2025 Annual Stockholders MeetingJune 6, 2025 | tipranks.comLifesci Capital Begins Coverage on Tectonic Therapeutic (NASDAQ:TECX)June 6, 2025 | marketbeat.comTectonic Therapeutic (TECX) Receives Outperform Rating and $87 Price Target | TECX Stock NewsJune 5, 2025 | gurufocus.comMillennium Management LLC Invests $1.33 Million in Tectonic Therapeutic (NASDAQ:TECX)June 4, 2025 | marketbeat.comTectonic Therapeutic Reports Q1 2025 Financial ResultsMay 31, 2025 | tipranks.comWoodline Partners LP Has $6.01 Million Holdings in Tectonic Therapeutic (NASDAQ:TECX)May 26, 2025 | marketbeat.com29,702 Shares in Tectonic Therapeutic (NASDAQ:TECX) Purchased by Jane Street Group LLCMay 22, 2025 | marketbeat.comPromising Phase 1b Results and Market Potential Drive Buy Rating for Tectonic Therapeutic’s TX45May 22, 2025 | tipranks.comSoleus Capital Management L.P. Makes New Investment in Tectonic Therapeutic (NASDAQ:TECX)May 21, 2025 | marketbeat.comTectonic Therapeutic Announces Phase 1b Trial ResultsMay 19, 2025 | tipranks.comPromising Phase 1b Results and Favorable Safety Profile Justify Buy Rating for Tectonic TherapeuticMay 19, 2025 | tipranks.comAnalysts Offer Insights on Healthcare Companies: Tectonic Therapeutic (TECX) and Amgen (AMGN)May 17, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIPHYF, TECX, ITOS, and HUMA Company DescriptionsHumacyte NASDAQ:HUMA$2.37 -0.04 (-1.66%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$2.38 +0.00 (+0.21%) As of 06/13/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Innate Pharma OTCMKTS:IPHYF$1.74 0.00 (0.00%) As of 06/13/2025Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.iTeos Therapeutics NASDAQ:ITOS$10.17 +0.19 (+1.90%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$10.17 0.00 (0.00%) As of 06/13/2025 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.Tectonic Therapeutic NASDAQ:TECX$21.89 -0.55 (-2.45%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$21.89 0.00 (0.00%) As of 06/13/2025 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
